EGFR and non-small cell lung carcinoma: More recently Rosell and colleagues have shown that in serum DNA taken from patients enrolled in a multicenter, randomized study of customized cisplatin-based chemotherapy in stage IV NSCLC (clinicaltrials.gov.identifier: NCT00174629) who subsequently underwent second-line chemotherapy or treatment with EGFR tyrosine kinase inhibitors (TKIs) that if the gene for checkpoint with forkhead-associated [41] and ring finger (RF) (CHFR) gene was hypo- or unmethylated in patients receiving second-line EGFR (TKIs), this was associated with longer survival [42].